Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2012
2012
Ventac Partners is a dedicated life science investment and consulting firm with offices in Europe, USA and Asia. Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting. All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.
2020
2020
Cube Labs is the first systematic venture builder in the healthcare technology space in Italy, designed to address the gap between the excellent local academic science and the commercially promising life sciences market. We build new companies from leading-edge R&D and enable innovation in order to transform pioneering science into healthcare solutions. From our roots in Italy, we have grown into a pan-European company with a distinguished international management team and a global reach. Partnerships are the pillars of our operations. Our partnership with the Italian National Institute for Biostructures and Biosystems (INBB), comprising 24 universities, grants us exclusive access to valuable commercial opportunities. We incorporate diverse competences into our organization through our global network. We work together with communities interested in innovation in order to transform outcomes for patients and accelerate the world’s transition to optimal health.
2023
2023
Eolo Pharma is a spin-off from the Institut Pasteur de Montevideo and UDELAR (Universidad de la República, Uruguay), we are a leading drug development and discovery platform company with a robust and versatile approach. Our focus lies in developing novel molecules to address non-communicable disorders such as cardiometabolic, neurodegenerative, and autoimmune disorders. Leveraging a decade of experience working with small molecules, we have built a unique portfolio based on patented technologies.
2023
2023
Next Generation Neuromodulation Solutions and Beyond: we develop a novel wirelessly powered neural interfacing technology enabling bi-directional communication with the nerve tissue.
2023
2023
2012
https://www.ut.ee/en/business
2012
BI3018 - Patenting and Commercialization of Biotech and Medtech Inventions Course content: Topics that will be covered in the course include Patenting: Principles, process, national/international laws, regulations and practice, similarities/differences between European and US patenting laws and practise. IPR strategies: Scientific/commercial aspects, how to develop an IP strategy to accelerate the innovation process and to safeguard IP investments, mastering freedom to operate in the Biotech/MedTech industry, Patent litigations, infringements and enforcements. Licensing: Models and negotiation strategies. Clinical testing: Design, implementation, analysis and presentation of clinical trials, adaptive clinical trial designs. Bio-tech/Med-tech business development: Strategy and organization when transferring a scientific idea into a commercial product/business, business plan development, product pipeline analysis, market analysis, market potential prediction, alliance structures and negotiation conditions, capital capture (pre-seed, seed, VC). Target group: Masters and PhD students, Tech Trans personnel, Biotech/Medtech staff, university academic staff
2013
2013
CAPTURE, DETECT & PRESERVE: ZipPrime has developed a novel circulating free DNA (cfDNA) capturing and preservation technology as a complete and dedicated pre-analytical workflow for early disease diagnosis. Instead of size selection-based of cfDNA extraction methods, ZipPrime’s technology prevents the loss of cfDNAs and improves the accuracy of cfDNA-based clinical diagnosis by tagging each and every cfDNA fragment, including the very rare cfDNA biomarkers, at a single molecule level. ZipPrime’s patented cfDNA capturing and preservation technology also allows the reusable storage, enrichment and subsequent testing of captured cfDNA fragments by constructing a reusable cfDNA biomarker library without the need for complicated devices or protocols. This disruptive cfDNA manipulation workflow creates a reusable cfDNA biomarker library template of the captured cfDNA fragments, which can be amplified, sequenced and/or re-analysed with any PCR-based protocol whenever required, even after long-term storage. Collaborations and licensing opportunities are currently being explored in several key fields.
2024
2024
2022
2022